Razer Blade Pro 17 review: big, bold, and powerful
A gaming laptop that doesn’t cut too many corners
from The Verge - All Posts https://ift.tt/2YL1zqZ
via IFTTT
from The Verge - All Posts https://ift.tt/2YL1zqZ
via IFTTT
6 investors discuss why AI is more than just a buzzword in biotech
As ChatGPT has so aptly demonstrated, AI is now truly entering the mainstream consciousness. That’s why we weren’t very surprised when a slew of investors told us they rarely see a biotech startup that doesn’t incorporate AI in some form or other these days. “Most of the companies we have seen have an AI component to support the discovery or development processes,” Francisco Dopazo, a general partner at Humboldt Fund told TechCrunch recently. But despite becoming quite the buzzword, AI’s apparent ubiquity in biotech isn’t actually driving deal flow or higher valuations. So to get a better idea of how AI is affecting biotech in 2022, we asked six investors to tell us what they look for in a biotech startup today. For Franck Lescure, a partner at Elaia Partners, in biotech, having an AI component isn’t an automatic deal closer. “We do not favor biotech startups with extant AI over those without: Bio-revolution is not only digital. Digital is one tool; the other major tool is the livin
Comments
Post a Comment